On the other hand, pharmacological inhibition of ErbB2 (HER2/neu) with the inhibitor lapatinib in breast cancer patients treated with doxorubicin increases the risk of developing heart failure compared to patients treated with doxorubicin alone39. The gene discussed is ERBB2; the disease is breast cancer.